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Summary
Objective: Transforming growth factor-b (TGF-b) has profound effects on chondrocyte proliferation and matrix production, and dysregulation
of TGF-b action has been implicated in osteoarthritis. The mechanisms by which the diverse actions of TGF-b are regulated in chondrocytes
are unclear. Although it is well documented that TGF-b signaling is transduced by types I and II receptors, other TGF-b receptors may play
critical roles by regulating signaling receptor activity. Our objective was to examine the expression of TbRII-B, a splice variant of the type II
TGF-b receptor, and to analyze its role in regulating TGF-b signaling in human chondrocytes.
Methods: TbRII-B expression was examined in human cartilage tissue specimens, human chondrocyte cell lines C28/I2 and tsT/AC62, and
human primary chondrocytes by Western blot and reverse-transcriptase-polymerase chain reaction. Ligand binding and heteromerization of
TbRII-B with other TGF-b receptors on the cell surface were analyzed by afﬁnity labeling, immunoprecipitation, and two-dimensional SDS-
PAGE. Regulation of TGF-b responses by TbRII-B was determined by examining Smad2 phosphorylation, Smad3-speciﬁc signaling,
transcriptional activity, and type II collagen levels.
Results: TbRII-B is expressed in normal and osteoarthritic human cartilage. Furthermore, it is a dynamic component of the TGF-b receptor
system in human chondrocytes, forming heteromeric complexes with the types I and II TGF-b receptors, betaglycan and endoglin. Importantly,
overexpression of TbRII-B leads to enhanced TGF-b signaling and responses in chondrocytes.
Conclusions: These results suggest that TbRII-B may play a key role in the regulation of TGF-b action in human chondrocytes.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Transforming growth factor-b (TGF-b) has a broad spec-
trum of effects on cartilage including regulation of chondro-
cyte proliferation, maintenance of phenotype, and matrix
turnover1,2. Dysregulation of TGF-b action has been impli-
cated in osteoarthritis (OA). Inhibition of endogenous
TGF-b during experimental OA has been shown to impair
articular cartilage repair3. In addition, mutant mice homozy-
gous for a targeted disruption of the Smad3 gene, a central
mediator of TGF-b signaling, and mice expressing dominant
negative type II TGF-b receptor in cartilage develop degen-
erative joint disease resembling human arthritis4,5. Con-
versely, excessive TGF-b action may play a role in the
pathogenesis of OA since TGF-b treatment has been re-
ported to result in OA-like lesions in rat knee joints6 and
to stimulate osteophyte outgrowth and proteoglycan deple-
tion in the murine knee joint7. Thus, either the deﬁciency or
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emphasizing the requirement for a tight regulation of TGF-
b action for the maintenance of chondrocyte phenotype
and function. However, the molecular mechanisms regulat-
ing TGF-b function in chondrocytes are poorly understood.
TGF-b is a multifunctional protein intricately involved in
growth, differentiation, and development8 and was de-
scribed initially as ‘cartilage inducing factor’9. Three distinct
isoforms of TGF-b (TGF-b 1, 2, and 3) which are encoded
by distinct genes have been described in mammals8. TGF-
b superfamily members signal through type I and type II
transmembrane serine/threonine kinase receptors10.
Ligand binding induces the formation or stabilization of
a complex in which the type II receptor (TbRII) transphos-
phorylates the type I receptor (TbRI). The activated type I
receptor then propagates the signal by phosphorylating
Smad2 and Smad3. These Smads then form heteromeric
complexes with Smad4 and translocate into the nucleus
where they control gene expression through interactions
with transcription factors, coactivators and corepressors11.
An alternatively spliced variant of the type II TGF-b receptor,
TbRII-B, which contains an insert of 26 amino acids replac-
ing Val32 of the type II receptor, has previously been re-
ported12. Accessory TGF-b receptors have been shown to
play an important role in modulating TGF-b signaling and
responses. These receptors include betaglycan (type III
TGF-b receptor) which binds all three TGF-b isoforms13,14,
and endoglin which binds the b1 and b3 but not b215e17.2
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TGF-b2 isoform to TbRII for which it has little afﬁnity on its
own18,19. However, we have previously shown that the
splice variant, TbRII-B, can bind TGF-b2 and mediate its
signaling in the absence of betaglycan20. More recently,
del Re et al. have reported that in the absence of
betaglycan, TbRII-B requires the type I receptor to bind
TGF-b221.
TGF-b receptor proﬁles on chondrocytes have been
poorly characterized. Identiﬁcation and functional character-
ization of novel TGF-b receptors on chondrocytes are
critical to understanding the mechanism of TGF-b action
in chondrocytes. We have recently reported that endoglin
is expressed on human chondrocytes and that it forms
a heteromeric complex with the signaling receptors and
betaglycan22. In the present study we examined the expres-
sion of TbRII-B in human normal and osteoarthritic cartilage
and chondrocytes in culture. In addition, we characterized
ligand binding properties of TbRII-B and its interaction
with signaling and accessory TGF-b receptors. Also, regula-
tion of TGF-b responses by TbRII-B was studied after
transient TbRII-B overexpression.
Materials and methods
ANTIBODIES
The anti-TbRII-B antibody speciﬁc for human TbRII-B
which recognizes a 20 amino acid peptide of the human
TbRII-B insert, was prepared as described previously20 or
was obtained from Dr H. Lin (Harvard Medical School,
Charleston, MA)21. Anti-type II (TbRII) antibody (C-20) was
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-endoglin antibody (SN6h) was purchased from
Dako Inc. (Carpinteria, CA). Anti-betaglycan antibody (Get1)23
and anti-phosphoSmad2 antibody24,25 were gifts from
Dr S. Souchelnytskyi (Uppsala, Sweden). Anti-type II
collagen antibody was a gift from Dr AR Poole, Montreal,
Quebec26. Anti-STAT3 antibody and the horseradish peroxi-
dase-conjugated anti-mouse, anti-rabbit and anti-goat
secondary antibodies and control IgG were all purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
CHONDROCYTE CELL LINES
The human chondrocyte cell lines (C28/I2 and tsT/AC62),
a gift from Dr M. Goldring (Beth Israel Deaconness Medical
Center, Harvard Institutes of Medicine, Boston, MA), have
been described previously27,28. The C28/I2 cell line was
developed using chondrocytes isolated from juvenile
human costal cartilage and by retroviral infection of those
chondrocytes with SV-40 large T antigen. tsT/AC62 cells
were developed using chondrocytes isolated from adult
human articular cartilage, by immortalization with a retrovi-
rus expressing a temperature-sensitive mutant of SV-40
large T antigen. This mutant is functional at 32C but not
at 37C28. These cells were incubated at 32C until conﬂu-
ence and transferred to 37C28 for experiments and
cultured for no longer than 3e4 days.
PRIMARY CHONDROCYTES
Human articular cartilage was obtained intraoperatively at
total joint arthroplasty from three adult patients diagnosed
as having OA or from three adults with traumatic open joint
injuries with no history of degenerative joint disease andnormal appearing cartilage (N). OA and normal cartilage
specimens were digested to obtain monolayer cultures as
previously described28. Brieﬂy, cartilage was incubated
with 0.25% trypsin (Invitrogen, Carlsbad, ON) for
30e45 min, and incubated overnight with hyaluronidase
and collagenase (both from Sigma Aldrich, Oakville, ON).
The suspension was pelleted, and plated at 1 106 cells/
ml. The growing monolayers, once conﬂuent, were
trypsinized and passaged.
CULTURE CONDITIONS
All chondrocytes were grown in DMEM/Ham’s F12 (1:1,
v:v) containing 10% fetal bovine serum (FBS), 100 U/ml
penicillin, 100 mg/ml streptomycin and 0.25 mg/ml amphoter-
icin (all from Invitrogen Life Technologies) and maintained
at 37C (32C for tsT/AC62) in 5% CO2/air. All experiments
were performed at early passage (passages 1e5) unless
stated otherwise.
CHONDROCYTE PROTEIN EXTRACTION
Total protein from human articular cartilage samples were
extracted using an SDS buffer as described previously29.
Brieﬂy, tissue was homogenized in SDS/solubilization
buffer ((20 mg 2-(N-cyclohexylamino) ethanesulfonic acid
(CHES), 40 mg SDS, 20 mg dithiothreitol (DTT), 200 ml
glycerol, in distilled water). The homogenate was boiled
for 5 min and centrifuged at 100,000 g for 2 h at 20C.
The pellet was resuspended in HEPES buffer (designated
as SDS preparation) and used for Western blot. Alterna-
tively, total protein was extracted using sucrose as
described previously30. Brieﬂy, the tissue was homogenized
using a Dounce homogenizer in homogenization buffer
(sucrose 0.25 M, EDTA 1 mM, HEPES 50 mM pH 7.5)
containing a mixture of protease inhibitors (1 mM phenylme-
thanesulfonyl ﬂuoride, 20 mgml1 aprotinin, 20 mgml1
leupeptin, 20 mgml1 soybean trypsin inhibitor, and
25 mM benzamidine; all from Sigma Aldrich). The homoge-
nate was then centrifuged and the pellet resuspended as
above (designated as sucrose preparation) and used for
Western blot.
Reverse-transcriptase-polymerase chain
reaction (RT-PCR)
Total RNAwas extracted from the human chondrocyte cell
line,C28/I2, and fromprimary human chondrocytes using Tri-
zol (Invitrogen, Carlsbad, CA), and reverse transcribed using
murine Maloney leukemia virus reverse transcriptase (Invi-
trogen) according to the manufacturer’s instructions. Sam-
ples were subjected to polymerase chain reaction (PCR)
using oligonucleotide primers that correspond to the extracel-
lular domain of TbRII (forward primer, nucleotides23 to4:
50-TATGACGAGCAGCGGGGTCT-30 and reverse primer,
nucleotides 435e417: 50-GTCATTGCACTCATCAGAG-30)20,31.
PCR was also performed using the TbRII-B speciﬁc forward
primer (nucleotides 106e132, 50-GAGGCCCAGAAAGAT
GAAATCATCTGC-30) in combination with the same reverse
primer used above, as described previously20. For PCR, Taq
polymerase (Invitrogen) was used with an initial denaturation
step for 5 min at 94C, followed by 35 cycles of denaturation
at 94C (30 s), annealing at 55C (45 s) and extension
at 72C (60 s). PCRproductswere resolved by 1.5%agarose
gel electrophoresis and visualized by ethidium bromide
staining.
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Chondrocytes were transfected with TbRII-B plasmid or
empty vector (EV, pCDNA1) using Lipofectamine (Invitro-
gen life Technologies), allowed to recover for 48 h and
cell lysates were prepared. In certain experiments, 48 h
after transfection, chondrocytes were serum starved for
4 h and treated with 50 pM of TGF-b1 for 15 min or were
left untreated, prior to preparation of cell lysates.
WESTERN BLOT
Western blotting was performed as previously de-
scribed22. All cell lysates and tissue extracts were standard-
ized for protein content and resolved by 3e11% gradient or
7.5% isocratic SDS-PAGE and immunoblotted with the indi-
cated antibodies. In certain experiments, the antibody was
neutralized by preincubation with the immunizing peptide
as a control. Equal protein loading was veriﬁed by reprobing
membranes with an anti-STAT3 antibody.
AFFINITY LABELING AND IMMUNOPRECIPITATION
OF TGF-b RECEPTORS
Afﬁnity labeling was performed as described previ-
ously22,32. Brieﬂy, cells were afﬁnity labeled with 100 pM
125I-TGF-b1 or 125I-TGF-b2 in the absence or presence
of varying concentrations of unlabeled TGF-b1, or -b2.
Solubilized membrane extracts were resolved by SDS-
PAGE (3e11% gradient) under nonreducing conditions
and analyzed by autoradiography. Alternatively, cells
were afﬁnity labeled and immunoprecipitation was per-
formed as described previously22,32. Brieﬂy, cells were
afﬁnity labeled with 200 pM 125I-TGF-b1 as above, and
the membrane extracts were incubated with the indicated
antibodies, preimmune serum or IgG (control). The
immune complexes were analyzed by SDS-PAGE
(3e11% gradient) under nonreducing conditions followed
by autoradiography.
IMMUNOPRECIPITATION/WESTERN BLOT ANALYSIS
Immunoprecipitation/Western blot was performed as pre-
viously described22. Monolayers of chondrocytes were
washed three times (10 min each time for a total of
30 min) at 4C with Dulbecco’s phosphate-buffered saline
(D-PBS) containing 0.1% bovine serum albumin (BSA), to
remove endogenous TGF-b bound to the receptors. Alter-
natively, cells were washed once with a mild acid (0.1%
glacial acetic acid) to ensure complete removal of endoge-
nous TGF-b, or were treated with 100 pM TGF-b. Previous
studies in our laboratory have shown that washing with
D-PBS/BSA over a 30 min period removed 85% (Gupta
and Philip, unpublished observations), and a mild acid
wash (0.1% glacial acetic acid) removed 95e100%, of
receptor-bound 125I-TGF-b32,33 (Philip and Garg, unpub-
lished observations). Chondrocyte cell lysates were then
prepared and immunoprecipitated with the indicated anti-
body (anti-betaglycan, anti-endoglin, or anti-TbRI antibody)
or control IgG, or were not immunoprecipitated. In some
experiments, chondrocytes were transfected with TbRI
and TbRII-B plasmids prior to preparation of cell lysates
and immunoprecipitation. The immune complexes and non-
immunoprecipitated extracts were resolved by SDS-PAGE
(3e11% gradient or 7.5% isocratic) and Western blot was
performed with the indicated antibody (anti-TbRII-B or
anti-endoglin antibody).TWO-DIMENSIONAL GEL ELECTROPHORESIS
Two-dimensional gel electrophoresis was performed as
previously described22,34. Solubilized membrane extracts
of cells afﬁnity labeled with 125I-TGF-b1 were fractionated
by SDS-PAGE under nonreducing conditions in the ﬁrst
dimension using a 1.0-mm-thick 3e11% gradient gel. An
individual lane was then cut out, placed horizontally on
top of a 1.5 mm-thick 3e11% gradient gel and analyzed un-
der reducing conditions in the second dimension. The gel
was then subjected to autoradiography. Alternatively, solu-
bilized membrane extracts were prepared from cells not
afﬁnity labeled and membrane extracts were immunoprecip-
itated with an anti-TbRII antibody before subjecting to two-
dimensional electrophoresis as above. The gel was then
analyzed by Western blot with the anti-TbRII-B antibody.
LUCIFERASE REPORTER ASSAY
Cellular responsiveness to TGF-b was examined using
3TP-Lux, a TGF-b-inducible promoter-reporter construct35,
or (CAGA)12-Luc, a Smad3-speciﬁc reporter construct, as
described previously22,36. Chondrocytes were transiently
transfected with TbRII-B plasmid or TbRII plasmid, or the
EV, and cotransfected with 3TP-Lux or (CAGA)12-Luc
and b-galactosidase (b-gal), using Lipofectamine. Cells
were allowed to recover for 48 h in regular medium, serum
starved for 4 h and then incubated overnight (18 h) in
serum-free media alone or containing the indicated concen-
trations of TGF-b1, TGF-b2, and TGF-b3. Cells were then
lysed and luciferase and b-gal activities determined as de-
scribed previously22,36. Luciferase activity was expressed
as a percentage of the activity in control untreated cells.
All values were normalized to b-galactosidase activity to
adjust for transfection efﬁciency. Statistical signiﬁcance
was determined using the Student’s t-test for unpaired
samples. A ‘P value’ of less than 0.05 considered to be
signiﬁcant.
Results
TbRII-B IS EXPRESSED IN HUMAN CHONDROCYTES
AND NORMAL AND OSTEOARTHRITIC CARTILAGE
The tsT/AC62 and C28/I2 human chondrocyte cell lines
have been demonstrated to be a reproducible model that
mimics human articular and costal phenotypes, respective-
ly37e40. We have previously characterized the human pri-
mary chondrocytes to demonstrate the expression of
cartilage-speciﬁc genes, type II collagen and aggrecan,
and the TGF-b responsiveness of these cells22. The results
shown in Fig. 1(A) demonstrate that human articular (tsT/
AC62) and nonarticular (C28/I2) chondrocytes express
TbRII-B endogenously, as detected by Western blot with
an antibody20 speciﬁc for TbRII-B, in EV transfected cells.
The electrophoretic mobility of TbRII-B overexpressed in
tsT/AC62 and C28/I2 cells (lanes 1 and 3, respectively) is
similar to that of endogenous TbRII-B detected in EV trans-
fected (lanes 2 and 4, respectively) cells. Equal protein
loading was conﬁrmed by reprobing the membrane with
an anti-STAT3 antibody (lower panel).
We then examined the expression of TbRII-B and TbRII in
human primary chondrocytes prepared from normal and os-
teoarthritic cartilage. Western blot of cell lysates of chondro-
cytes from osteoarthritic cartilage using an anti-TbRII
antibody (a-RII) detected both TbRII and TbRII-B (left panel),
as expected, while the TbRII-B antibody (a-RII-B) detected
445Osteoarthritis and Cartilage Vol. 15, No. 4Fig. 1. Expression of TbRII-B in human chondrocytes. A: Human chondrocyte cell lines C28/I2 and tsT/AC62 were transfected with TbRII-B
(RIIB) or its EV, and solubilized cell extracts, containing equal amounts of protein, were analyzed by Western blot using an anti-TbRII-B
antibody (upper panel). Equal protein loading was ascertained by reprobing the membrane with an anti-STAT3 antibody (lower panel).
B: Human primary chondrocytes were prepared from cartilage specimens by enzymatic digestion and cultured as monolayers. Solubilized
cell extracts, containing equal amounts of protein, were analyzed by Western blot using an anti-TbRII antibody (a-RII, left panel), an anti-TbRII
antibody preincubated with blocking peptide (a-RIIþBP, middle panel) or an anti-TbRII-B antibody (a-RIIB, right panel). C: Total protein
extracts of osteoarthritic (OA) and normal (N) cartilage tissue samples were prepared using an SDS-containing buffer. Alternatively, the
OA and N cartilage samples were digested with enzymes or cultured as monolayers from which solubilized cell lysates were prepared.
The tissue protein extracts (SDS preparation, left panel) and the solubilized cell lysates of chondrocytes, containing equal amounts of protein
(monolayers, right panel), were analyzed by Western blot using an anti-TbRII-B antibody (RIIB, upper panel). Equal protein loading was
conﬁrmed by reprobing the membrane with an anti-STAT3 antibody (STAT3, lower panel). D: Total RNA was extracted from primary human
chondrocytes or C28/I2 cells and subjected to RT-PCR (þ) or PCR without RT () as described in Materials and Methods. PCR products
corresponding to the expected sizes of TbRII-B and TbRII are shown. The data shown are representative of three different experiments
(A, B, C, D).only TbRII-B (right panel) [Fig. 1(B)]. Similar results were
obtained with primary chondrocytes prepared from normal
human cartilage (data not shown). Preincubation of the
anti-TbRII antibody with its immunizing peptide (a-RIIþBP)
blocked the detection of TbRII-B and TbRII bands (middle
panel), demonstrating the antibody speciﬁcity.
To conﬁrm that TbRII-B is expressed in normal and
osteoarthritic cartilage, we determined TbRII-B expression
in protein extracts prepared from those tissues [Fig. 1(C),
left panel]. TbRII-B expression was also determined in
monolayers of chondrocytes from those tissues, for conﬁr-
mation [Fig. 1(C), right panel]. These results demonstrate
that TbRII-B is expressed in OA and normal cartilage, as
well as in primary cultures of chondrocytes prepared from
those tissues [Fig. 1(C), left vs right panel]. Similar results
were obtained using cartilage protein extracts prepared
using a sucrose-containing buffer, instead of the SDS-
containing buffer used above (data not shown). Equal pro-
tein loading in each lane was demonstrated by reprobing
the membrane with an anti-STAT3 antibody [Fig. 1(C), bot-
tom panel]. Although we have observed enhanced levels of
TbRII-B in OA cartilage as compared to normal cartilage in
the samples analyzed, it is not possible to conclude that
TbRII-B expression is upregulated in OA cartilage due tothe small number of samples analyzed. A larger number
of samples that are controlled for variables such as age,
sex, cartilage zones, other health parameters and age
related changes in cartilage would be required to conﬁrm
that TbRII-B expression is elevated in OA cartilage.
The expression of TbRII-B and TbRII at the mRNA level
in human chondrocytes was conﬁrmed by RT-PCR using
oligonucleotide primers that amplify both TbRII and TbRII-
B and with primers that speciﬁcally amplify TbRII-B. As
demonstrated in Fig. 1(D), PCR performed with RNA from
primary chondrocytes and C28/I2 cells using the ﬁrst set
of primers generates two PCR products, 458 bp and
536 bp, which correspond to the expected sizes of TbRII
and TbRII-B amplicons, respectively (upper panel, lanes 2
and 4). Importantly, PCR performed with the second set
of primers generates a single band of approximately
330 bp, which corresponds to the expected size of the
TbRII-B amplicon (lower panel, lanes 2 and 4). No PCR
products were produced in the absence of reverse tran-
scription (upper and lower panels, lanes 1 and 3), indicating
that the PCR products were derived from TbRII/TbRII-B
mRNA and not from contamination due to genomic DNA.
These results demonstrate that both TbRII and TbRII-B
mRNA are expressed in human chondrocytes.
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HIGH AFFINITY FOR TGF-b1 AND A LOW AFFINITY FOR TGF-b2
To deﬁne the relative ligand binding afﬁnity of TbRII-B
on chondrocytes, C28/I2 cells were afﬁnity labeled with
125I-TGF-b1 and competition proﬁles were generated with
unlabeled TGF-b1 and -b2 [Fig. 2(A)]. Afﬁnity labeling
with 125I-TGF-b1 in the absence of unlabeled ligand (lanes
designated as ‘0’) reveals binding complexes of relative
molecular weights of 65 kDa, 85 kDa, 145 kDa and
180 kDa under nonreducing conditions. We have
previously shown22 that these complexes correspond to
TbRI, TbRII, TbRIeTbRII heterodimer (or TbRIeTbRII-B
heterodimer, as suggested by the present study) and en-
doglin dimer, respectively [Fig. 2(A)]. The band detected
at 95 kDa was conﬁrmed as TbRII-B later by immunopre-
cipitation studies using speciﬁc anti-receptor antibodies
[Fig. 3(A)]. The relatively low exposure did not allow the
detection of betaglycan (TbRIII) in this particular experi-
ment. It is apparent from the results shown in Fig. 2(A)
that TbRII-B has high afﬁnity for the TGF-b1 isoform as
evidenced by the displacement of 125I-TGF-b1 with in-
creasing concentrations of unlabeled TGF-b1. This is con-
sistent with our previous ﬁndings20. TbRII-B displays
a modest afﬁnity for the TGF-b2 isoform under these con-
ditions as evidenced by a lack of competition at 5
(0.5 nM), 10 (1.0 nM), and 20 (2.0 nM) concentrations
of unlabeled TGF-b2. However, direct binding of TGF-b2
by TbRII-B (and TbRII) is detectable when the cells are la-
beled with 125I-TGF-b2 [Fig. 2(B), lane ‘0’], although the
band detected is weaker than when the cells are labeled
with 125I-TGF-b1 [Fig. 2(B) vs (A)]. Similar results were ob-
tained using tsT/AC62 cells (data not shown). The band at
180 kDa corresponding to the endoglin dimer is detectable
when cells are labeled with 125I-TGF-b1 [Fig. 2(A)], but not
when they are labeled with 125I-TGF-b2 [Fig. 2(A)], as ex-
pected since endoglin does not bind TGF-b215,41. The
band at 145 kDa corresponding to either TbRIeTbRII or
TbRIeTbRII-B heterodimer22 is detectable when cells are
labeled with 125I-TGF-b1 or 125I-TGF-b2 [Fig. 2(A) and
(B), respectively], as expected.TbRII-B ASSOCIATES WITH TGF-b SIGNALING RECEPTORS AS
WELL AS ACCESSORY RECEPTORS AND FORMS HIGHER
ORDER COMPLEXES WITH THESE RECEPTORS ON HUMAN
CHONDROCYTES
We have previously shown in COS-7 cells that TbRII-B is
able to form complexes with the TGF-b signaling recep-
tors20. To conﬁrm that such associations occur on human
chondrocytes, tsT/AC62 cells were afﬁnity labeled with
125I-TGF-b1 and cell lysates were immunoprecipitated
with an anti-TbRII-B antibody. As expected, SDS-PAGE
analysis (under nonreducing conditions) of cell lysates not
immunoprecipitated [Fig. 3(A), NIP, lane 1] demonstrates
the presence of TbRI, TbRII, TbRII-B, the 145 kDa band
(corresponding to TbRIeTbRII or TbRIeTbRII-B), endoglin
dimer, and betaglycan. Importantly, the anti-TbRII-B anti-
body immunoprecipitated TbRII-B and coimmunoprecipi-
tated TbRI and small amounts of TbRII, endoglin and
betaglycan [a-RII-B, Fig. 3(A), lane 2]. Since the anti-
TbRII-B antibody is speciﬁc for TbRII-B and does not recog-
nize other receptors, coimmunoprecipitation of TbRI, TbRII,
betaglycan or endoglin by this antibody is indicative of het-
eromeric complex formation of TbRII-B with those recep-
tors. Immunoprecipitation with IgG did not precipitate any
receptors [Fig. 3(A), IgG, lane 3].
The association of TbRII-B with other TGF-b receptors
on human chondrocytes was further examined by two-
dimensional (nonreducing/reducing) gel electrophoresis of
membrane extracts of chondrocytes afﬁnity labeled with
125I-TGF-b1. Results shown in Fig. 3(B) indicate that high
molecular weight receptor complexes occur in the region
of 180 kDa, 240 kDa and 320 kDa under nonreducing con-
ditions [designated as 3, 2, and 1, respectively, in Fig. 3(B)].
Different spots of identical mobilities as the endoglin mono-
mer, TbRII-B and TbRII or TbRI, fell from these complexes
under reducing conditions. A likely explanation for the pres-
ence of four spots (endoglin monomer, TbRII-B and TbRII
or TbRI) under the 180 kDa region is that, under nonreduc-
ing conditions, the endoglin dimer, which has an approxi-
mate molecular weight of 180 kDa, comigrates with other
heteromeric complexes of similar molecular weights whichFig. 2. TbRII-B demonstrates high afﬁnity for TGF-b1 and a low afﬁnity for TGF-b2 on human chondrocytes. Conﬂuent monolayers of C28/I2
cells were afﬁnity labeled with 100 pM of 125I-TGF-b1 (A) or 125I-TGF-b2 (B) in the absence or presence of indicated concentrations of
unlabeled TGF-b1 or TGF-b2. Solubilized membrane extracts were analyzed by SDS-PAGE (3e11% gradient) under nonreducing conditions
followed by autoradiography. The data shown are representative of three different experiments.
447Osteoarthritis and Cartilage Vol. 15, No. 4Fig. 3. TbRII-B forms heteromeric complexes with other TGF-b receptors on human chondrocytes in the presence of ligand. A: tsT/AC62 cells
were afﬁnity labeled with 100 pM of 125I-TGF-b1 and solubilized membrane extracts were left not immunoprecipitated (NIP, lane 1) or immu-
noprecipitated with 3 mg/ml of anti-TbRII-B antibody (a-RIIB, lane 2) or IgG (lane 3). Complexes were fractionated by SDS-PAGE (3e11%
gradient gels) under nonreducing conditions and visualized by autoradiography. B: tsT/AC62 cells were afﬁnity labeled with 100 pM
of 125I-TGF-b1 and solubilized membrane extracts were analyzed by SDS-PAGE (3e11% gradient gel) under nonreducing conditions in
the ﬁrst dimension. The individual lane was then cut out, laid horizontally on a second gel (3e11% gradient) and analyzed under reducing
conditions in the second dimension, and subjected to autoradiography. Radiolabelled spots under the diagonal correspond to endoglin
(Eg), TbRII-B (RIIB), and TbRII (RII) as reported previously based on their relative sizes, speciﬁc binding to TGF-b, and immunoprecipitation
data22. C: tsT/AC62 cells were washed three times (10 min each time for a total of 30 min) at 4C with D-PBS/BSA and cell lysates were im-
munoprecipitated with an anti-TbRII antibody (RII). The immune complexes were then analyzed by nonreducing/reducing two-dimensional
electrophoresis as in B. The gel was then analyzed by Western blot with an anti-TbRII-B antibody (RIIB). TbRII-B was detected on the diagonal
(spot 1) and below the diagonal in the region of 180 kDa, 240 kDa and 320 kDa (spots 2, 3 and 4, respectively). The data shown (A, B and C)
are representative of three different experiments.contain TbRII-B, TbRII or TbRI in various combinations.
Under reducing conditions, the 180 kDa endoglin dimer
would be expected to give rise to two endoglin monomers,
and the heteromeric complexes, containing TbRII-B, TbRII,
or TbRI, migrating in the 180 kDa region would be expected
to generate TbRII-B, TbRII, or TbRI monomers. The
240 kDa and 320 kDa complexes are also reductant-sensi-
tive, and again spots of identical mobilities as the endoglin
monomer, TbRII-B, TbRII, and TbRI fell from those posi-
tions suggesting that these receptors are associated with
each other, and occur as higher order complexes. Together,
these results are consistent with the notion that TbRII-B
heteromerizes with TbRII, TbRI and endoglin to form higher
order complexes in the presence of ligand.
The above results demonstrate that TbRII-B forms higher
order complexes with other TGF-b receptors, as detected
by afﬁnity labeling. We then veriﬁed the interaction of these
receptors using an alternative approach, namely,
immunoprecipitation in tandem with two-dimensional
electrophoresis and Western blot [Fig. 3(C)]. Thus, celllysates prepared from chondrocytes were immunoprecipi-
tated with an anti-TbRII antibody and two-dimensional gel
electrophoresis was performed as above, followed by
immunoblotting with an anti-TbRII-B antibody. The anti-
TbRII-B antibody detected a spot of identical molecular
weight as TbRII-B, in four regions, one on the diagonal
and the other three at approximately 180 kDa, 240 kDa or
320 kDa (designated as 1, 2, 3, or 4, respectively). Spot 1
located on the diagonal likely represents un-complexed
TbRII-B. Importantly, TbRII-B fell from higher molecular
weight complexes of 180 kDa, 240 kDa, and 320 kDa.
Since anti-TbRII antibody can recognize both TbRII and
TbRII-B, the 180 kDa may represent a heterodimer of TbRII
and TbRII-B, or a homodimer of TbRII-B. However, the
240 kDa and 320 kDa complexes likely represent hetero-
meric complexes of TbRII-B with other TGF-b receptors
since homotrimeric or homotetrameric TGF-b receptor
complexes have not been shown to exist. These results
are consistent with the data obtained using afﬁnity labeling
[Fig. 3(B)], and support the notion that TbRII-B forms higher
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these data suggest that such complex formation occurs in
a ligand-independent manner since the experiments were
performed in the virtual absence of TGF-b.
We then examined the interaction of TbRII-Bwith TbRI, en-
doglin and betaglycan using immunoprecipitation in tandem
with Western blot. Chondrocytes were washed with a mild
acid (0.1% glacial acetic acid) or with D-PBS/1% BSA to re-
move endogenous TGF-b bound to the receptors, or treated
with 100 pM TGF-b1 as described in Methods. Cell lysates
containing equal amounts of protein were immunoprecipi-
tated with the indicated antibodies and the complexes ana-
lyzed by Western blot using anti-TbRII-B or anti-endoglin
antibody (Fig. 4). Immunoblotting of nonimmunoprecipitated
cell lysateswith theanti-TbRII-Bantibody conﬁrmed thepres-
ence of TbRII-B in chondrocytes (NIP, Fig. 4, lanes 1 and 5).
TbRII-B was coimmunoprecipitated with the anti-TbRI anti-
body in cell lysates prepared from chondrocytes that were
washed with a mild acid (a-RI/acid, Fig. 4, lane 3) or treated
with TGF-b1 (a-RI/TGF-b, Fig. 4, lane 4). In addition, TbRII-
B was coimmunoprecipitated using anti-endoglin (a-Eg,
Fig. 4, lane 7) or anti-betaglycan (a-BG, Fig. 4, lane 8) anti-
body in cell lysates prepared from chondrocytes washed
with D-PBS/BSA. In addition, immunoprecipitation of cell
Fig. 4. TbRII-B forms heteromeric complexes with other TGF-b
receptors on chondrocytes in the absence of ligand. C28/I2 cells
were transfected with TbRI and TbRII-B plasmids and 48 h after
transfection, were washed with 0.1% glacial acetic acid or treated
with 100 pM TGF-b1 for 1 h at 37C (upper panel). Alternatively,
nontransfected cells were washed three times (10 min each time
for a total of 30 min) at 4C with D-PBS/BSA (middle and lower
panels). Cell lysates were prepared and left nonimmunoprecipitated
(NIP, lanes 1 and 5), immunoprecipitated with 3 mg/ml each of anti-
TbRI (a-RI, lanes 3 and 4), anti-endoglin (aeEg, lanes 7 and 9),
anti-betaglycan (a-BG, lane 8) or anti-TbRII-B (aeRIIB, lane 10)
antibody or IgG (lanes 2 and 6). Samples were fractionated on
SDS-PAGE (3e11% gradient gels) and were analyzed by Western
blot with anti-TbRII-B (upper and middle panels) or anti-endoglin
(lower panel) antibody. The data shown are representative of two
different experiments.lysates with the anti-TbRII-B antibody detected endoglin in
a Western blot using an anti-endoglin antibody, conﬁrming
the coimmunoprecipitation of TbRII-B and endoglin (a-RIIB,
Fig. 4, lane 10). A control experiment showing the Western
blot of endoglin immunoprecipitatedwith ananti-endoglin an-
tibody conﬁrms the presence of endoglin on chondrocytes (a-
Eg, Fig. 4, lane 9). No TbRII-B was detected when immuno-
precipitation was done with a control IgG (IgG, Fig. 4, lanes
2 and6). The coimmunoprecipitation of TbRII-Bwith endoglin
and betaglycanwasdetectable at physiological receptor con-
centrations whereas the coimmunoprecipitation of TbRI with
TbRII-B became readily detectable only after transfection of
TbRI and TbRII-B. Importantly, experiments performed in
the virtual absence of TGF-b (acid or PBS/BSA wash) dem-
onstrate that TbRII-B forms a complex with TbRI (lane 3), en-
doglin (lane 7) or betaglycan (lane 8) in a ligand-independent
manner in chondrocytes. There was no signiﬁcant difference
between association of TbRII-B with TbRI in chondrocytes
washed with a mild acid and in chondrocytes to which exog-
enous TGF-bwas added (Fig. 4, lane 3 vs lane 4). The similar
amounts of the IgG (Fig. 4, lanes 2, 3 and 4; lower panel) de-
tected indicate that equal amounts of immune complexes
were loaded in each lane (Fig. 4, lane 3 vs lane 4).
OVEREXPRESSION OF TbRII-B ENHANCES TGF-b-INDUCED
SMAD2 PHOSPHORYLATION, SMAD3-SPECIFIC SIGNALING
AND TRANSCRIPTIONAL ACTIVITY IN HUMAN
CHONDROCYTES
To examine the functional signiﬁcance of TbRII-B
expression in human chondrocytes, we determined TGF-
b-induced Smad2 phosphorylation, Smad3-driven signaling
and transcriptional activity using human chondrocytes
overexpressing TbRII-B. Results shown in Fig. 5(A) demon-
strate that both basal (lane 3 vs lane 1, upper panel) and
TGF-b-induced (lane 4 vs lane 2, upper panel) Smad2
phosphorylation is upregulated in tsT/AC62 chondrocytes
overexpressing TbRII-B when compared to EV transfected
cells. Similar results were obtained using C28/I2 cells
(data not shown). That the lanes were loaded with equal
amounts of protein was conﬁrmed by reprobing the mem-
brane with an anti-STAT3 antibody [Fig. 5(A), lower panel].
Since differential activation of Smad2 and Smad3 have
been reported42,43, it was important to determine the effect
of TbRII-B on Smad3-speciﬁc signaling. We thus examined
whether TbRII-B activates Smad3-driven signaling using
(CAGA)12-luc, a Smad3-speciﬁc reporter plasmid. Results
shown in Fig. 5(B) demonstrate that TbRII-B overexpres-
sion enhances basal and TGF-b1-induced (CAGA)12-luc
activity as compared to the EV transfected cells
(P< 0.05). These data suggest that TbRII-B can activate
both Smad2 and Smad3 signaling in human chondrocytes.
We then analyzed the effect of TbRII-B overexpression
on gene transcriptional activity in response to TGF-b1,
TGF-b2 and TGF-b3 isoforms in chondrocytes using the
3TP-Lux reporter assay. Data shown in Fig. 5(C) illustrate
that overexpression of TbRII-B in tsT/AC62 cells results in
enhanced transcriptional activity in the absence of TGF-
b as compared to EV transfected control (P< 0.05). Impor-
tantly, overexpression of TbRII-B results in markedly
enhanced transcriptional activity in response to TGF-b1 or
TGF-b3 (P< 0.05) while there was no signiﬁcant difference
in the activity in response to the TGF-b2 isoform as com-
pared to empty vector transfected cells. In comparison,
TbRII overexpression in chondrocytes resulted in enhanced
transcriptional activity (P< 0.05) in response to both TGF-b1
and TGF-b2 but not TGF-b3.
449Osteoarthritis and Cartilage Vol. 15, No. 4Fig. 5. Overexpression of TbRII-B enhances basal and TGF-b-induced responses in human chondrocytes. A: Overexpression of TbRII-B
stimulates Smad2 phosphorylation: tsT/AC62 chondrocytes were transiently transfected with TbRII-B (RIIB) or EV. After 48 h cells were
treated with 50 pM of TGF-b1 for 15 min (þ) or left untreated () and were analyzed by Western blot using anti-phospho Smad2 antibody
(upper panel). The membrane was reprobed with an anti-STAT3 antibody to illustrate equal protein loading (lower panel). B: Overexpression
of TbRII-B stimulates Smad3-dependent signaling: C28/I2 cells were transfected with TbRII-B or EV along with the Smad3-speciﬁc luciferase
construct, (CAGA)12-luc and b-gal. Cells were then treated with 0, 2.5, 5 or 10 pM TGF-b1 for 18 h and the cell lysates were analyzed for
luciferase and b-gal activities. Data are expressed as fold-increase (mean standard deviation (SD)) in luciferase activity relative to EV (con-
trol) transfected cells that were not treated with TGF-b1 (*P< 0.05). C: Overexpression of TbRII-B stimulates TGF-b-induced transcriptional
activity: tsT/AC62 chondrocytes were transiently transfected with TbRII (RII), TbRII-B (RIIB), or EV along with 3TP-Lux and b-gal. Forty-eight
hours after transfection, cells were treated with 100 pM of TGF-b1, b2, or b3 for 24 h or were left untreated (). Luciferase activity was
determined, normalized using the b-gal assay. Data are expressed as a fold-increase relative to cells not treated with TGF-b (*P< 0.05). Sim-
ilar results were obtained with C28/I2 cells. D: Overexpression of TbRII-B enhances collagen expression: tsT/AC62 chondrocytes were tran-
siently transfected with TbRII-B (RII-B) or EV. After 48 h, cell lysates were analyzed by Western blot using an anti-type II collagen antibody
(upper panel). The membrane was reprobed with an anti-STAT3 antibody to conﬁrm equal protein loading (lower panel). The results shown
(A, B, C, D) are representative of three different experiments.OVEREXPRESSION OF TbRII-B ENHANCES TYPE II COLLAGEN
EXPRESSION IN HUMAN CHONDROCYTES
To explore the role of TbRII-B on extracellular matrix
production in chondrocytes, we determined the effect of
TbRII-B overexpression on type II collagen production.
Results shown in Fig. 5(D) illustrate that overexpression
of TbRII-B leads to enhanced collagen type II content in
tsT/AC62 cells as determined by Western blot using an
anti-type II collagen antibody (upper panel). Similar results
were obtained with C28/I2 cells (data not shown). The
membrane was reprobed with an anti-STAT3 antibody to
demonstrate equal protein loading (lower panel).
Discussion
TGF-b is a key modulator of chondrocyte proliferation, dif-
ferentiation, extracellular matrix production, and thereby
chondrocyte phenotype and reparative capacity2. Despite
the well-documented effects of TGF-b on cartilage homeo-
stasis and function, the regulation of TGF-b signaling in
chondrocytes is poorly deﬁned. Alterations in TGF-b recep-
tor proﬁles and receptor subtype composition may contrib-
ute to the dysregulation of TGF-b signaling and alteredphenotype exhibited by osteoarthritic chondrocytes. In the
present study we show that TbRII-B, an alternatively spliced
form of the type II TGF-b receptor, is expressed in normal
and osteoarthritic human cartilage, as well as human
primary chondrocytes, and chondrocyte cell lines. The phe-
notype of the human chondrocyte cell lines and primary
chondrocytes used in the present study has been charac-
terized previously22,37e40, and they have been shown to
express both type II collagen and aggrecan mRNAs, and
respond to TGF-b22. Using these cells, we demonstrate
that TbRII-B forms a heteromeric complex with not only
the types I and II signaling receptors but also with the ac-
cessory receptors, betaglycan and endoglin. Furthermore,
overexpression of exogenous TbRII-B in chondrocytes is
associated with enhanced basal and TGF-b-induced
Smad2 phosphorylation, Smad3 signaling, transcriptional
activity and type II collagen production.
The functional signiﬁcance of TbRII-B expression and its
potential regulation of TGF-b signaling in chondrocytes
have not been addressed previously. Although a previous
study has shown that human chondrocytes express
TbRII-B at the mRNA level44, its expression at the protein
level has not previously been reported in this cell type.
Also, its ligand binding properties, interaction with other
TGF-b receptors and modulation of TGF-b signaling in
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analysis of ligand binding by TbRII-B in human chondro-
cytes reveals a several-fold higher afﬁnity for TGF-b1
than for the TGF-b2 isoform. However, TbRII-B does exhibit
a modest afﬁnity for the TGF-b2 isoform on chondrocytes
as evidenced by the direct binding of this isoform when
cells are labeled with 125I-TGF-b2. The low afﬁnity of
TbRII-B for TGF-b2 in chondrocytes is consistent with the
absence of a signiﬁcant effect of this isoform on TGF-b-in-
ducible gene transcriptional activity we observed in this cell
type [Fig. 5(C)]. In a previous study, we have shown that
TbRII-B, unlike TbRII, is capable of binding TGF-b2 in the
absence of betaglycan20. More recently, others have dem-
onstrated that TGF-b2 binding by TbRII-B requires the
presence of TbRI21. It is not possible to estimate the true
afﬁnity of TbRII-B for the TGF-b isoforms on chondrocytes
from the results obtained in the present study since betagly-
can and the TbRI present on these cells preclude such
estimation.
Analysis of the association of TbRII-B with other recep-
tors on chondrocytes, using afﬁnity labeling/coimmunopre-
cipitation, reveals that TbRII-B forms a heteromeric
complex with TbRI and TbRII as well as with betaglycan
and endoglin in the presence of ligand. The association of
TbRII-B with TbRI, TbRII and endoglin in the presence of
TGF-b is also evident from the results obtained by two-
dimensional electrophoresis. The complex formation of
TbRII-B with TbRI and TbRII and betaglycan in the pres-
ence of ligand in chondrocytes, is consistent with our previ-
ous ﬁnding in other cell types after overexpression20. Our
ﬁnding in the present study showing that TbRII-B interacts
with endoglin is novel; however, the signiﬁcance of this in-
teraction remains to be determined. Negative regulation of
TGF-b signaling by endoglin has been shown in other cell
types45. Thus, it is possible that endoglin may negatively
modulate TbRII-B signaling in chondrocytes. Together, our
results demonstrating that TbRII-B interacts with TbRI,
TbRII, betaglycan and endoglin on chondrocytes in the
presence of ligand, suggest that TbRII-B is a dynamic com-
ponent of the TGF-b signaling complex in these cells.
An important ﬁnding in the present study is that TbRII-B is
most likely associated with TbRI, betaglycan and endoglin
on chondrocytes in the absence of TGF-b ligand. The
30 min washing procedure (Philip and Garg, unpublished
observations) or a mild acid wash32,33,46 used in the present
study has previously been shown to remove most of endog-
enous TGF-b bound to receptors. Importantly, the associa-
tion of TbRII-B with the other receptors occurs at
endogenous receptor concentrations (in the presence or
absence of TGF-b) since our studies were performed using
untransfected human chondrocytes. Although the complex
formation of TbRII-B with TbRI in the absence of TGF-b be-
comes readily detectable only after overexpression of those
receptors, this may not be due to an absence of interaction,
but may reﬂect the relatively low abundance of TbRI as
compared to endoglin and betaglycan on the cell surface
and the low sensitivity of the detection method. Our ﬁnding
that the addition of TGF-b does not appear to increase the
amounts of TbRII-B coimmunoprecipitated with anti-TbRI
antibody is intriguing. However, it has previously been
shown that TGF-b addition does not alter heteromeric com-
plex formation between TbRII and TbRI47.
That TbRII-B forms complexes with the other TGF-b re-
ceptors in a ligand-independent manner implicates the
presence of preexisting heteromeric receptor complexes in-
dependent of ligand occupancy. Thus, ligand binding may
occur when those receptors are components of a preexistingreceptor complex on the cell surface, as opposed to TGF-b
inducing the association of these receptors. The association
of TbRII-B with TbRI in the absence of ligand is reminiscent
of the previous reports that TbRII and TbRI have intrinsic af-
ﬁnity for each other and that these two receptor types stay
associated on the cell surface in the absence of ligand47e50.
It is therefore not surprising that TbRII-B, which is identical
to TbRII except for a 26 amino acid insertion, can associate
with TbRI in the absence of ligand. Similarly, our ﬁnding that
TbRII-B associates with endoglin in the absence of ligand is
consistent with the previous reports by others showing the
ligand-independent association of endoglin with TbRII as
well as with TbRI, and Alk-1, a type I TGF-b receptor17,51.
The similar degree of association between TbRII-B and
TbRI both in the presence and absence of TGF-b, raises
questions regarding the role of ligand binding and how
the spontaneous activation of TbRI by TbRII (and/or
TbRII-B) and signaling are prevented. The precise mecha-
nism by which ligand binding may induce TGF-b receptor
activation and signaling is poorly understood. Several
studies have suggested that ligand co-occupancy is
required for the physical association of TbRI with TbRII,
leading to the phosphorylation of TbRI by TbRII and sig-
naling35. However, there is now increasing evidence to
suggest that ligand can bind to a preexisting complex
and it has been proposed that ligand binding to such com-
plexes may induce a conformational alteration allowing
exposure of phosphorylation sites and subsequent trans-
phosphorylation TbRI by TbRII and activation of the signal-
ing pathway47,50,52. On the basis of results obtained using
a cell free system, del Re et al. have recently suggested
that TbRIeTbRII-B interaction with the ligand is coopera-
tive involving ligand binding to a TbRIeTbRII-B complex
in which the two receptors are in direct contact21. It is
possible that ligand-independent receptor complexes may
exist in parallel with the ligand-induced receptor com-
plexes, and may specify distinct signaling pathways.
Interestingly, it has been shown for bone morphogenetic
protein receptors that preformed heteromeric receptor
complexes, in which ligand binding occurs only subse-
quently, exhibit differential signaling from that of ligand-in-
duced heteromeric receptor complexes53.
The cell surface interactions between TbRII-B and other
TGF-b receptors resulting in the formation of hetero-oligo-
meric complexes of different subtype composition may
deﬁne signaling speciﬁcity, and thus the diverse TGF-b re-
sponses in chondrocytes. Whether the receptor complexes
containing TbRII-BeTbRII heteromers are functionally dis-
tinct from those containing TbRII homodimers or TbRII-B
homodimers remains to be determined. Similarly, it is not
known how signaling from a TbRII-BeTbRI complex may
differ from that of a TbRIIeTbRI complex.
Studies of the regulation of TGF-b signaling by TbRII-B in
chondrocytes reveal that transient overexpression of TbRII-
B results in enhanced TGF-b-induced responses as de-
tected by increased Smad2 phosphorylation, Smad3-driven
signaling and gene transcriptional activity. It is not known
whether the increased collagen expression in cells overex-
pressing TbRII-B involves, Smad2, Smad3, or both. Al-
though it is likely that the increased TGF-b-induced
3TPLux activity in chondrocytes overexpressing TbRII-B is
due to Smad3 signaling, the involvement of mitogen acti-
vated protein kinases cannot be ruled out54,55. The exper-
imental conditions used in the present study do not allow us
to conclude whether the enhanced Smad2 phosphorylation,
Smad3 signaling, transcriptional activity and collagen pro-
duction observed in TbRII-B transfected chondrocytes
451Osteoarthritis and Cartilage Vol. 15, No. 4under basal conditions are due to a ligand-independent ef-
fect or an autocrine effect.
In summary, our results show that TbRII-B, an alterna-
tively spliced form of the type II TGF-b receptor, is
expressed in normal and OA human chondrocytes. In addi-
tion, we show that TbRII-B is a dynamic component of the
TGF-b receptor system in human chondrocytes by demon-
strating that it forms heteromeric complexes with the types I
and II TGF-b signaling receptors as well as with betaglycan
and endoglin on the chondrocyte cell surface. That this
complex formation may occur even in the absence of ligand
suggests that ligand binds to preexisting complexes in addi-
tion to the ligand-induced formation of receptor complexes.
Importantly, transient overexpression of TbRII-B leads to
enhanced TGF-b responses in chondrocytes. Taken to-
gether, our ﬁndings strongly suggest that TbRII-B plays
a critical role in regulating TGF-b signaling in chondrocytes
and thus chondrocyte function. Speciﬁc alterations in the
levels or ratios of the individual TGF-b receptor subtypes
during cellular dedifferentiation may result in modulation of
TGF-b responses. Whether chondrocyte dedifferentiation
or OA is associated with changes in TbRII-B expression,
resulting in altered TGF-b responses remains to be
determined.
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